Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering the company's expertise in biotechnology, drug delivery, and central nervous system clinical development. The additions come as Helus Pharma advances its pipeline of novel serotonergic agonists (NSAs), including programs targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Dr. Langer, a renowned figure in biotechnology and drug delivery, has authored over 1,500 articles and holds more than 1,400 patents. His contributions have significantly impacted the field of controlled drug release. Dr. Brannan, with over 30 years of experience in CNS drug development, has led numerous clinical programs, including the development of antidepressants and antipsychotics. Their expertise will guide Helus Pharma's disciplined, evidence-based drug development approach.
Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for GAD. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways, promoting neuroplasticity and addressing unmet needs in mental health.
"We are thrilled to welcome Dr. Langer and Dr. Brannan to our Scientific Advisory Board," said a spokesperson for Helus Pharma. "Their unparalleled expertise will be invaluable as we progress our pipeline and work to improve outcomes for patients suffering from depression and anxiety."
The appointments underscore Helus Pharma's commitment to advancing mental health treatments. For more information, visit the company's website at https://www.helus.com. The full press release is available at https://ibn.fm/CyjTq.
